Next 10 |
home / stock / hnsbf / hnsbf news
2024-04-18 14:22:55 ET More on Hansa Biopharma Hansa Biopharma AB (publ) 2024 Q1 - Results - Earnings Call Presentation Hansa Biopharma AB (publ) (HNSBF) Q1 2024 Earnings Call Transcript Hansa Biopharma AB (publ) 2023 Q4 - Results - Earnings Call Presentation ...
2024-04-18 11:45:23 ET Hansa Biopharma AB (publ). (HCHDF) Q1 2024 Earnings Conference Call April 18, 2024, 08:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Hitto Kaufmann - C...
2024-04-02 10:17:06 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma Read the full article on Seeking Alpha For further details see: Hansa Biopharma expects to report revenue of about SEK 54...
2024-02-02 14:30:04 ET Hansa Biopharma AB (publ) (HNSBF) Q4 2023 Earnings Conference Call February 02, 2024 8:00 AM ET Company Participants Søren Tulstrup – Chief Executive Officer Matt Shaulis – Chief Commercial Officer and U.S. President Hitt...
2024-02-02 03:15:55 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma Read the full article on Seeking Alpha For further details see: Hansa Biopharma GAAP EPS of -SEK2.40, revenue of SEK50.4M
2024-01-08 10:42:44 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma For further details see: Hansa Biopharma expects to report Q4 total revenue of SEK 50M
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
2023-10-26 19:30:24 ET Hansa Biopharma AB (publ) (HNSBF) Q3 2023 Results Conference Call October 26, 2023 08:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Donato Spota - Chie...
2023-10-26 12:42:13 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma For further details see: Hansa Biopharma reports Q3 results
2023-07-20 13:58:09 ET Hansa Biopharma AB (publ) (HNSBF) Q2 2023 Earnings Call Transcript July 20, 2023 08:00 AM ET Company Participants Soren Tulstrup - President and CEO Matthew Shaulis - CCO Donato Spota - SVP and CFO Conference Call Participants G...
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients PR Newswire Idefirix ® becomes the first and only product recommended by SMC...